lncRNA MEG3 inhibits pituitary tumor development by participating in cell proliferation, apoptosis and EMT processes

Wang,Xuejian; Li,Xiangdong; Wang,Zhifeng

doi:10.3892/or.2021.7991

lncRNA MEG3 inhibits pituitary tumor development by participating in cell proliferation, apoptosis and EMT processes

Authors:
- Xuejian Wang
- Xiangdong Li
- Zhifeng Wang
View Affiliations

Affiliations: Department of Neurosurgery, First Affiliated Hospital of Soochow University, Soochow University, Soochow, Jiangsu 225000, P.R. China, Department of Neurosurgery, Affiliated Hospital 2 of Nantong University, Nantong University, Nantong, Jiangsu 226000, P.R. China
Published online on: February 23, 2021 https://doi.org/10.3892/or.2021.7991
Article Number: 40
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pituitary tumors do not pose a threat to life but can cause visual disturbances and serious clinical syndromes, such as infertility and metabolic syndrome. Therefore, screening of key genes involved in the occurrence and development of pituitary tumors can provide new targets for the treatment of pituitary tumors. The aim of the present study was to investigate the molecular mechanism of long non‑coding (lnc.) RNA maternally expressed 3 (MEG3) in cell proliferation, apoptosis and epithelial‑mesenchymal transition (EMT) processes of pituitary tumor. Tissue samples were obtained from 34 patients who underwent surgical treatment of pituitary tumors. Pituitary tumor cells (GH3 and MMQ) were transfected with pcDNA3.1(+)‑MEG3, short hairpin (sh)MEG3, microRNA (miR)‑23‑3p inhibitor or their controls using Lipofectamine^® 2000. Reverse transcription‑quantitative PCR and western blot analyses were used to detect the levels of MEG3, miR‑23b‑3p and FOXO4, as well as proliferation‑, apoptosis‑ and EMT‑associated genes and proteins. Cell Counting Kit‑8 and flow cytometry assays were performed to detect proliferation and apoptosis, and Transwell assay was undertaken to assess invasion and migration. Luciferase reporter and RNA pulldown assays were performed to verify the binding between lncRNA MEG3, miR‑23b‑3p and FOXO4. Pearson's correlation analysis was used to analyze the correlation between expression levels of MEG3, miR‑23b‑3p and FOXO4. lncRNA MEG3 was expressed at lower levels in pituitary tumor tissues and cells. Overexpression of lncRNA MEG3 inhibited proliferation, invasion and migration and accelerated apoptosis of pituitary tumor cells. lncRNA MEG3 negatively regulated miR‑23b‑3p expression levels, while miR‑23b‑3p negatively regulated FOXO4 expression levels. Overexpression of lncRNA MEG3 inhibited the EMT process in pituitary tumor cells. miR‑23‑3p inhibitor rescued the effect of shMEG3 on proliferation, invasion, migration, apoptosis and the EMT process in pituitary tumor cells. lncRNA MEG3 inhibited pituitary tumor development by participating in cell proliferation, apoptosis and the EMT process, which may present a novel target for pituitary tumor treatment.

View Figures

View References

1	Haddad N, Tedoro AJ and Soares NP: Carotenoids inhibits cell proliferation, arrest cell cycle and induces apoptosis in pituitary tumor cells. 13th European Congress of Endocrinology. BioScientifica; 2011
2	Hui L, Shengwu C and Mingwei Z: Surgical treatment of pituitary adenoma: Analysis of 508 cases at a single institution. Chin J Oncol Surg. 5:42013.
3	Sheary CB: Possible influence of orthodontics on pituitary gland function and learning ability. J Clin Orthod. 19:889–890. 1985.PubMed/NCBI
4	Bürgi U and Seiler R: Hypophyseal dysfunction and tumors. Ther Umsche. 49:136–141. 1992.(In German).
5	Rao G and Apfelbaum RI: Symptomatic pneumocephalus occurring years after transphenoidal surgery and radiation therapy for an invasive pituitary tumor: A case report and review of the literature. Pituitary. 6:49–52. 2003. View Article : Google Scholar : PubMed/NCBI
6	Bolognani F, Albariño CG, Romanowski V, Carri NG and Goya RG: In vitro and in vivo herpetic vector-mediated gene transfer in the pituitary gland: Impact on hormone secretion. Eur J Endocrinol. 145:497–503. 2001. View Article : Google Scholar : PubMed/NCBI
7	Santoro A, Minniti G, Ruggeri A, Esposito V, Jaffrain-Rea ML and Delfini R: Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: Long-term endocrinologic follow-up results. Surg Neurol. 68:513–518. 2007. View Article : Google Scholar : PubMed/NCBI
8	Zhong A, Pu J, Ruan L, Jin J, Tan S, Wang F, Mou J and Yang G: The complications of endoscopic transsphenoidal surgery for pituitary neoplasms. Int J Clin Exp Med. 9:20026–20031. 2016.
9	Prensner JR and Chinnaiyan AM: The emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407. 2011. View Article : Google Scholar : PubMed/NCBI
10	Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et al: The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 47:1992015. View Article : Google Scholar : PubMed/NCBI
11	Zhou K, Li S, Du G, Fan Y, Wu P, Sun H and Zhang T: LncRNA XIST depletion prevents cancer progression in invasive pituitary neuroendocrine tumor by inhibiting bFGF via upregulation of microRNA-424-5p. Onco Targets Ther. 12:7095–7109. 2019. View Article : Google Scholar : PubMed/NCBI
12	Zhang Y, Liu YT, Tang H, Xie WQ, Yao H, Gu WT, Zheng YZ, Shang HB, Wang Y, Wei YX, et al: Exosome-transmitted lncRNA H19 inhibits the growth of pituitary adenoma. J Clin Endocrinol Metab. 104:6345–6356. 2019. View Article : Google Scholar : PubMed/NCBI
13	D'Angelo D, Mussnich P, Sepe R, Raia M, Del Vecchio L, Cappabianca P, Pellecchia S, Petrosino S, Saggio S, Solari D, et al: RPSAP52 lncRNA is overexpressed in pituitary tumors and promotes cell proliferation by acting as miRNA sponge for HMGA proteins. J Mol Med (Berl). 97:1019–1032. 2019. View Article : Google Scholar : PubMed/NCBI
14	Wang C, Tan C, Wen Y, Zhang D, Li G, Chang L, Su J and Wang X: FOXP1-induced lncRNA CLRN1-AS1 acts as a tumor suppressor in pituitary prolactinoma by repressing the autophagy via inactivating Wnt/β-catenin signaling pathway. Cell Death Dis. 10:4992019. View Article : Google Scholar : PubMed/NCBI
15	Zhu H, Jing G, Shen Y, Dong W, Gao H, Miao Y, Li C and Zhang Y: Functions and mechanisms of tumor necrosis factor-α and noncoding RNAs in bone-invasive pituitary adenomas. Clin Cancer Res. 24:5757–5766. 2018. View Article : Google Scholar : PubMed/NCBI
16	Yue X, Dong C, Ye Z, Zhu L, Zhang X, Eang X, Mo F, Li Z and Pan B: LncRNA SNHG7 sponges miR-449a to promote pituitary adenomas progression. Metab Brain Dis. 36:123–132. 2021. View Article : Google Scholar : PubMed/NCBI
17	Modali SD, Parekh VI, Kebebew E and Agarwal SK: Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol. 29:224–237. 2015. View Article : Google Scholar : PubMed/NCBI
18	Liu LX, Deng W, Zhou XT, Chen RP, Xiang MQ, Guo YT, Pu ZJ, Li R, Wang GF and Wu LF: The mechanism of adenosine- mediated activation of lncRNA MEG3 and its antitumor effects in human hepatoma cells. Int J Oncol. 48:421–429. 2016. View Article : Google Scholar : PubMed/NCBI
19	Modali SD, Desai SS, Parekh VI, Kebebew E, Emmert-Buck M and Agarwal SK: Abstract LB-249: Reduced expression of the long non-coding RNA MEG3 in sporadic and MEN1-associated tumors. Cancer Res. 79 (Suppl 8):LB–249. 2013.
20	Fan FY, Deng R, Yi H, Sun HP, Zeng Y, He GC and Su Y: The inhibitory effect of MEG3/miR-214/AIFM2 axis on the growth of T-cell lymphoblastic lymphoma. Int J Oncol. 51:316–326. 2017. View Article : Google Scholar : PubMed/NCBI
21	Mezzomo LC, Gonzales PH, Pesce FG, Kretzmann Filho N, Ferreira NP, Oliveira MC and Kohek MB: Expression of cell growth negative regulators MEG3 and GADD45γ is lost in most sporadic human pituitary adenomas. Pituitary. 15:420–427. 2012. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Method. 25:402–408. 2001. View Article : Google Scholar
23	Zhang J, Yao T, Lin Z and Gao Y: Aberrant methylation of MEG3 functions as a potential plasma-based biomarker for cervical cancer. Sci Rep. 7:62712017. View Article : Google Scholar : PubMed/NCBI
24	Kouhara H, Tatekawa T, Koga M, Hiraga S, Arita N, Mori H and Sato B: Intracranial and intraspinal dissemination of an ACTH-secreting pituitary tumor. Endocrinol Jpn. 39:177–184. 1992. View Article : Google Scholar : PubMed/NCBI
25	Shimon I and Melmed S: Pituitary tumor pathogenesis. J Clin Endocrinol Metab. 82:1675–1681. 1997. View Article : Google Scholar : PubMed/NCBI
26	Tian ZZ, Guo XJ, Zhao YM and Fang Y: Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma. Int J Clin Exp Pathol. 8:15138–15142. 2015.PubMed/NCBI
27	Hu D, Su C, Jiang M, Shen Y, Shi A, Zhao F, Chen R, Shen Z, Bao J and Tang W: Fenofibrate inhibited pancreatic cancer cells proliferation via activation of p53 mediated by upregulation of LncRNA MEG3. Biochem Biophys Res Commun. 471:290–295. 2016. View Article : Google Scholar : PubMed/NCBI
28	Kim Y, Noren Hooten N and Evans MK: CRP stimulates GDF15 expression in endothelial cells through p53. Mediators Inflamm. 2018:82780392018. View Article : Google Scholar : PubMed/NCBI
29	House JS, Hall J, Park SS, Planchart A, Money E, Maguire RL, Huang Z, Mattingly CJ, Skaar D, Tzeng JY, et al: Cadmium exposure and MEG3 methylation differences between Whites and African Americans in the NEST cohort. Environ Epigenet. 5:dvz0142019. View Article : Google Scholar : PubMed/NCBI
30	Gejman R, Batista DL, Zhong Y, Zhou Y, Zhang X, Swearingen B, Stratakis CA, Hedley-Whyte ET and Klibanski A: Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 93:4119–4125. 2008. View Article : Google Scholar : PubMed/NCBI
31	Cheunsuchon P, Zhou Y, Zhang X, Lee H, Chen W, Nakayama Y, Rice KA, Tessa Hedley-Whyte E, Swearingen B and Klibanski A: Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas. Am J Pathol. 179:2120–2130. 2011. View Article : Google Scholar : PubMed/NCBI
32	Su W, Xie W, Shang Q and Su B: The long noncoding RNA MEG3 is downregulated and inversely associated with VEGF levels in osteoarthritis. Biomed Res Int. 2015:3568932015. View Article : Google Scholar : PubMed/NCBI
33	Zaman MS, Thamminana S, Shahryari V, Chiyomaru T, Deng G, Saini S, Majid S, Fukuhara S, Chang I, Arora S, et al: Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer. PLoS One. 7:e502032012. View Article : Google Scholar : PubMed/NCBI
34	Zhou K, Zhang T, Fan Y, Du G, Wu P and Geng D: MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN. Tumour Biol. 37:13469–13477. 2016. View Article : Google Scholar : PubMed/NCBI
35	Li B, Sun M, Gao F, Liu W, Yang Y, Liu H, Cheng Y, Liu C and Cai J: Up-regulated expression of miR-23a/b targeted the pro-apoptotic Fas in radiation-induced thymic lymphoma. Cell Physiol Biochem. 32:1729–1740. 2013. View Article : Google Scholar : PubMed/NCBI
36	Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L, Zhuang L, Luo J, Chen H, Liu L, et al: MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology. 145:1133–1143.e12. 2013. View Article : Google Scholar : PubMed/NCBI
37	Folmer F, Orlikova B, Schnekenburger M, Dicato M and Diederich M: Naturally occurring regulators of histone acetylation/deacetylation. Curr Nutr Food Sci. 6:78–99. 2010. View Article : Google Scholar
38	Chuang PY, Dai Y, Liu R, He H, Kretzler M, Jim B, Cohen CD and He JC: Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One. 6:e235662011. View Article : Google Scholar : PubMed/NCBI
39	Lam EF, Francis R and Petkovic M: FOXO transcription factors: Key regulators of cell fate. Biochem Soc Trans. 34:722–726. 2006. View Article : Google Scholar : PubMed/NCBI
40	Urbich C, Knau A, Fichtlscherer S, Walter DH, Brühl T, Potente M, Hofmann WK, de Vos S, Zeiher AM and Dimmeler S: FOXO-dependent expression of the proapoptotic protein Bim: Pivotal role for apoptosis signaling in endothelial progenitor cells. FASEB J. 19:974–976. 2005. View Article : Google Scholar : PubMed/NCBI
41	Brenkman AB, van den Broek NJ, de Keizer PL, van Gent DC and Burgering BM: The DNA damage repair protein Ku70 interacts with FOXO4 to coordinate a conserved cellular stress response. FASEB J. 24:4271–4280. 2010. View Article : Google Scholar : PubMed/NCBI
42	Zuo JH, Zhu W, Li MY, Li XH, Yi H, Zeng GQ, Wan XX, He QY, Li JH, Qu JQ, et al: Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem. 112:2508–2517. 2011. View Article : Google Scholar : PubMed/NCBI
43	Klymkowsky MW and Savagner P: Epithelial-mesenchymal transition: A cancer researcher's conceptual friend and foe. Am J Pathol. 174:1588–1593. 2009. View Article : Google Scholar : PubMed/NCBI